A Russian company will conduct cancer drug trials in the United States
The Russian biopharmaceutical company Incuron, which develops innovative anti-cancer drugs, has received permission from the American Food and Drug Administration (FDA) for clinical trials of the drug CBL0137 for the treatment of patients with progressive malignant tumors, RIA Novosti reports with reference to JSC RVC.
"Obtaining FDA approval for the study of an innovative molecule in the United States by a Russian startup is a precedent case in Russian practice," said Vladimir Tezov, CEO of the Bioprocess Capital Partners management company, who is quoted in the message.
Incuron is a Russian company founded in 2010 by the Bioprocess Capital Ventures Fund, created with the participation of RVC and Vnesheconombank capital, and private investor Cleveland BioLabs. The company is a participant of the Skolkovo project. Incuron is developing fundamentally new anti–cancer drugs based on kuraxins - small molecules with a potentially wide range of therapeutic applications. Curaxins can also be used to treat certain autoimmune diseases and inflammatory conditions.
The management company "Bioprocess Capital Partners" is the trustee of the fund "Bioprocess Capital Ventures". The Fund invests in innovative projects in the field of biotechnology and fine chemistry, the size of the fund is three billion rubles.
Portal "Eternal youth" http://vechnayamolodost.ru11.04.2013